160 related articles for article (PubMed ID: 23340996)
1. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
Lupus; 2013 Mar; 22(3):268-78. PubMed ID: 23340996
[TBL] [Abstract][Full Text] [Related]
2. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
J Med Econ; 2013; 16(4):500-9. PubMed ID: 23363329
[TBL] [Abstract][Full Text] [Related]
3. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Dec; 39(12):2303-9. PubMed ID: 23027885
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
6. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population.
Furst DE; Amato AA; Iorga SR; Bancroft T; Fernandes AW
Muscle Nerve; 2012 Oct; 46(4):496-505. PubMed ID: 22987689
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
8. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
[TBL] [Abstract][Full Text] [Related]
9. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease.
Karve S; Candrilli S; Kappelman MD; Tolleson-Rinehart S; Tennis P; Andrews E
J Pediatr; 2012 Oct; 161(4):662-670.e2. PubMed ID: 22578787
[TBL] [Abstract][Full Text] [Related]
11. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
Slawsky KA; Fernandes AW; Fusfeld L; Manzi S; Goss TF
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1224-32. PubMed ID: 21584945
[TBL] [Abstract][Full Text] [Related]
12. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
15. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
Clarke AE; Urowitz MB; Monga N; Hanly JG
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
[TBL] [Abstract][Full Text] [Related]
17. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
18. Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus.
Park SY; Joo YB; Shim J; Sung YK; Bae SC
Rheumatol Int; 2015 Nov; 35(11):1809-15. PubMed ID: 26254885
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Rheumatology (Oxford); 2009 May; 48(5):564-8. PubMed ID: 19269959
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.
Kan H; Guerin A; Kaminsky MS; Yu AP; Wu EQ; Denio A; Priti J; Narayanan S; Molta C
J Med Econ; 2013; 16(6):793-800. PubMed ID: 23647447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
